Tag:
Johnson & Johnson
Latest Headlines
Latest Headlines
Altura Medical draws in $6M for AAA treatment device work
Altura Medical has grabbed $6 million in new venture equity financing, according to a regulatory filing.
Eric Perakslis leaves top IT job at FDA
The FDA has lost another chief information officer. After leading an IT reboot at the agency for less than two years, Eric Perakslis left his position effective March 5 and an interim CIO will serve until a permanent replacement is found, FDA spokeswoman Sandy Walsh said in an email to FierceBiotech IT .
Which drugs are the biggest duds in blockbuster-land?
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
J&J releases more Doxil to the market
Johnson & Johnson and the FDA sprang into action in 2011 when J&J's popular chemo drug Doxil became hard to get because of problems with the contract manufacturer. But it also figured out a process by which it could have it manufactured at one plant and finished at another.
Medtronic, J&J race toward artificial pancreas
Despite all the advances in medical devices for Type 1 diabetes, nothing resembling an artifical pancreas has made its way to the market stateside, but companies like Medtronic, Johnson & Johnson and Tandem are working to push the technology forward.
More Doxil made through J&J 'alternative manufacturing'
While the FDA has yet to give its final sign-off to this creative work-around, it has permitted the Johnson & Johnson subsidiary to release a lot at a time, the latest last week.
Pharmacyclics bounces higher as J&J wins third 'breakthrough' cancer drug coup
Already sky-high expectations for the experimental cancer drug ibrutinib from J&J and Pharmacyclics managed to arc even higher this morning after the collaborators spread word that the program had just won its third "breakthrough drug" title from the FDA.
J&J recalls Animas insulin pumps over hypoglycemia risk
Animas, Johnson & Johnson's insulin pump unit, is recalling its 2020 devices, warning that a malfunction may lead to unintended insulin delivery and put patients at risk.
J&J victory: Appeals court tosses $482M stent patent defeat
A federal appeals court threw out a radiologist's $482 million patent infringement victory against Johnson & Johnson, validating the Cypher drug-eluting stents once produced by its Cordis subsidiary. One man's victory against a giant corporation lasted about two years.
J&J, Pfizer chip in on $18M round for anti-inflammatory biotech's PhII
The venture arms for Johnson & Johnson and Pfizer have helped spearhead an $18 million investment round for Canada's Aquinox Pharmaceuticals as the biotech plots the next big step in a mid-stage program for its lead anti-inflammatory drug.
